CAR T-cell therapy for young people with lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests a treatment that uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. It is for young people whose lupus is active despite trying several standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 25 years old or younger.
- You have been diagnosed with systemic lupus erythematosus (lupus) using standard classification criteria.
- You have tried at least three lupus treatments, including corticosteroids, such as hydroxychloroquine, methotrexate, cyclophosphamide, or others.
- Your lupus affects a major organ, like the kidneys, heart, lungs, or blood (with low platelets or hemolytic anemia).
- Your lupus is currently active, with a score of 10 or higher on the SLEDAI-2K scale.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment called CD19 CAR T-cell therapy for people with severe lupus that hasn't improved with standard treatments. It uses your own immune cells to target and destroy the faulty cells causing lupus symptoms.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This study tests a new treatment using a type of immune cell therapy (CAR T-cells) for people with moderate to severe systemic lupus erythematosus (SLE) that has not responded well to standard treatments. The therapy aims to reset the immune system to reduce lupus activity.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
This trial tests an experimental therapy called IC19 CAR-T cells, which are specially modified immune cells, for people with severe lupus that hasn't gotten better with standard treatments. The goal is to see if this therapy can calm the immune system and reduce lupus symptoms.
Hear when a new Childhood-Onset Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.